Figure 2 shows marked early attrition in three of the seven cohorts (C3 FF/FS, FF/SS, and SS/FF), and there was a highly significant difference between patient survival within the different C3 genotypes at 30 d posttransplant ( P = 0.01 by Mantel-Cox log-rank analysis).
A numerical benefit to freedom from rejection emerged in both the separate donor and recipient C3 FF cohorts, but this failed to reach significance ( P = 0.28 and 0.14, respectively, at 2500 days).
Patient survival to 2500 days in 478 cases stratified according to the presence or absence of the complement C3 F allele showed marginal benefit to the absence of the C3 F allele, which was maintained to 2500 days but did not achieve significance: 81% survival for the C3 SS/SS subgroup vs. 84%, 86%, and 86% in the FX/FX, FX/SS, and SS/FX cohorts ( P = 0.58 at 2500 days; Supplementary Table 1 ).